Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where L. Santos is active.

Publication


Featured researches published by L. Santos.


Transplantation Proceedings | 2003

Liver transplantation for fulminant and subfulminant hepatic failure.

O Núñez-Martı́nez; G De la Cruz; A de Diego; J. Molina; Diego Rincón; L. Santos; Ana Matilla; Rafael Bañares; M. Salcedo; Jose Luis Calleja; G. Clemente

AIMS The aim of this study was to assess the long-term course and outcome after liver transplantation (LTX) for fulminant/subfulminant hepatic failure (FSHF) to determine which factors relate to outcome. PATIENTS AND METHODS Between April 1990 and October 2002, 30 adult patients with FSHF underwent LTX. Kings College criteria were used to decide which patients needed LTX. Pretransplantation parameters (age, sex, degree of hepatic encephalopathy, etiology, and time between onset of symptoms and LTX) were examined as risk factors for LTX outcome. RESULTS Mean age at LTX was 40.4+/-13.9 years and 46.7% were men. The most frequent causes of FSHF were virus B in 23.3%, autoimmune hepatitis in 23.3%, and cryptogenic in 20%. Fifty percent of the patients with a survival longer than 15 days suffered episodes of acute rejection; chronic rejection occurred in 25%. One- and five-year patient and allograft survival rates for FSHF were 56.3% and 54.7%, respectively. Autoimmune hepatitis was the only factor associated with better posttransplantation outcome, although there were no differences in posttransplant course. Patient survival rates increased during the study period. During the first 5 years (1990-1995) the survival rates were 53.3% (1-year and 5-year), whereas they were 60% at 1 and 5 years in the second interval (1996-2002). CONCLUSIONS The mortality rate of FSHF is high during the first year post-LTX. LTX for FSHF of autoimmune etiology showed better outcomes with increasing patient survival rates during the study period.


Transplant International | 2000

Modulation of ICAM‐1 tissue expression in patients with liver transplantation (LT) and acute rejection (AR) after glucocorticoid treatment

Marjorie Romero; C.García Monzón; G. Clemente; Magdalena Salcedo; Rafael Bañares; E. Alvarez; A. de Diego; L. Santos; R. Moreno Otero

Abstract Acute rejection (AR) is a frequent complication following liver transplantation (LT). ICAM‐1 may be involved in its pathogenesis. High doses of glucocorticoids are the standard treatment in these patients. The aim of this study was to describe corticoid effects on ICAM‐1 tissue expression in liver biopsies of patients with LT and AR. The study included liver biopsies performed before and after treatment in 12 patients with LT and proven AR. In 10 patients AR was reversible and in 2, was steroid resistant. For immunohistochemistry, an indirect immunoperoxidase technique was used. Each histology section was semiquantitatively evaluated as follows: 0: <10% staining, 1: 10‐25%, 2: 25‐50%, 3: >50%. The control group comprised nine patients with LT and normal liver biopsies. In pre‐treatment liver biopsy samples, ICAM‐1 was markedly expressed on sinusoidal cells (2.41 ± 0.66), and there was also expression on periportal (0.66 ± 0.65) and perivenular hepatocytes (0.83 ± 0.57). By contrast, in the liver tissue from the control group, sinusoidal ICAM‐1 reactivity was significantly lower (0.88 ± 0.33; P < 0.05), and hepatocytes showed no reliable ICAM‐1 expression. After steroid treatment the intensity of ICAM‐1 decreased significantly in sinusoids (1.5 ± 0.67; P < 0.05) and in perivenular hepatocytes (0.25 ± 0.86; P < 0.05). Additionally, we also observed a decreased ICAM‐1 reactivity in portal hepatocytes (0.25 ± 0.62), but these differences did not reach statistical significance. Remarkably, after treatment, hepatocytes did not show ICAM‐1 reactivity in resolved AR, but in corticoid‐resistant patients AR did not change or increase. In conclusion, in patients with LT and AR, ICAM‐1 was expressed in hepatocytes and with more intensity in sinusoid cells. Additionally, a down‐regulation of the ICAM‐1 tissue expression after corticoid treatment may exist, although in corticoid‐resistant AR no modulation on ICAM‐1 tissue expression was observed.


Transplant International | 1998

Pulmonary complications following orthotopic liver transplant

Fg Durán; Belén Piqueras; M. Romero; J. A. Carneros; A. de Diego; Magdalena Salcedo; L. Santos; J. Ferreiroa; E. Cos; G. Clemente


Gastroenterología y Hepatología | 1999

[Arterial complications after liver transplantation: early and late forms].

A. de Diego; J. Ferreiroa; Jose Luis Calleja; L. Santos; Gerardo Clemente Ricote; A. Parera de Cáceres; M. Salavert; J. Vaquero Martín


Transplantation Proceedings | 1999

Cardiovascular risk factors and late cardiovascular disease in liver transplantation.

M. Romero; A Parera; Magdalena Salcedo; M Abeytua; Rafael Bañares; A de Diego; L. Santos; G. Clemente


Transplantation Proceedings | 1998

Late orthotopic liver retransplantation: indications and survival.

Fg Durán; Ra Cercadillo; L. Santos; A de Diego; J. Ferreiroa; E Valdecantos; G. Clemente


Gastroenterología y Hepatología | 2000

Factores pronósticos de supervivencia del carcinoma hepatocelular avanzado tras quimioembolización transarterial

R Álvarez; Rafael Bañares; A Echenagusía; Ja Carneros; L. Santos; G Simó; F Camúñez


Journal of Hepatology | 2000

Response to steroid treatment in “DE novo” autoimmune hepatitisafter liver transplantation in adults

Magdalena Salcedo; Rafael Bañares; M. Rodriguez-Mahou; E. Alvarez; Javier Vaquero; A. Hdez-Albújar; Diego Rincón; L. Santos; G. Clemente


Journal of Hepatology | 2004

233 Increased incidence of hepatocellular carcinoma (HCC) after transjugular intrahepatic portosystemic shunt (TIPS)

Rafael Bañares; M. Escudero; O. Nunez-Martinez; C. Fernandez; Javier Vaquero; I. Beceiro; G. Clemente; L. Santos; A. Echenagusia


Journal of Hepatology | 2003

Up-regulation of the inducible nitric oxide synthase expression in human hepatocytes by the non-structural 5A protein of the hepatitis C virus

Pedro L. Majano; M. Gomez; A. Apolinario; M. Lopez-Cabrera; O. Nunez; L. Santos; Magdalena Salcedo; A. Matilla; Diego Rincón; G. Clemente; C. Garcia-Monzon

Collaboration


Dive into the L. Santos's collaboration.

Top Co-Authors

Avatar

G. Clemente

Instituto de Salud Carlos III

View shared research outputs
Top Co-Authors

Avatar

Magdalena Salcedo

Complutense University of Madrid

View shared research outputs
Top Co-Authors

Avatar

Rafael Bañares

Complutense University of Madrid

View shared research outputs
Top Co-Authors

Avatar

Pedro L. Majano

Instituto de Salud Carlos III

View shared research outputs
Top Co-Authors

Avatar

A. Apolinario

Autonomous University of Madrid

View shared research outputs
Top Co-Authors

Avatar

C. Garcia-Monzon

Complutense University of Madrid

View shared research outputs
Top Co-Authors

Avatar

E. Alvarez

Complutense University of Madrid

View shared research outputs
Top Co-Authors

Avatar

Jose Luis Calleja

Autonomous University of Madrid

View shared research outputs
Top Co-Authors

Avatar

Belén Piqueras

Complutense University of Madrid

View shared research outputs
Researchain Logo
Decentralizing Knowledge